Dr Jordan Burgess

Dr Burgess’s clinical interests are anchored in venous thromboembolism and thrombophilia, with a particular focus on the optimisation of anticoagulation strategies and the management of their complications. He is actively involved in refining protocols for the investigation and treatment of thrombophilic disorders, and he contributes to the development of regional guidelines that standardise testing and reduce diagnostic error. His work in bleeding disorders encompasses both inherited conditions such as haemophilia and acquired coagulopathies, where he applies a nuanced understanding of haemostatic pathways to guide therapeutic decisions.

Equally passionate about haemoglobinopathies, Dr Burgess monitors patients with sickle cell disease and thalassaemia, addressing both disease‑specific complications and the broader implications for transfusion medicine. He remains engaged with diagnostic haematology, interpreting complex laboratory results and integrating them into clinical pathways for haematological malignancies, myelodysplastic syndromes, myeloproliferative neoplasms and AL amyloidosis. His interests also extend to clinical governance, where he analyses system failures and redesigns diagnostic pathways to enhance patient outcomes.

In a leadership capacity, Dr Burgess chairs the Thrombosis Multidisciplinary Team meeting and the local Thrombosis Committee, overseeing the development and implementation of anticoagulation and thrombosis management pathways. He has driven service improvement initiatives through guideline development, incident review and quality assurance projects, notably authoring a regional thrombophilia testing guideline and a regional thrombotic thrombocytopenic purpura (TTP) management guideline that have become benchmarks for evidence based practice.

Dr Burgess is a dedicated educator, regularly delivering undergraduate and postgraduate teaching sessions. He mentors junior doctors, clinical scientists and multidisciplinary staff, emphasizing diagnostic reasoning, haematology pathways and the principles of clinical governance. His instructional style blends case based learning with practical skills training, fostering a generation of clinicians equipped to manage sophisticated haematological problems.

His research agenda concentrates on immune mediated haematological disorders, including immune thrombocytopaenic purpura (ITP), autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP). Dr. Burgess seeks to elucidate pathogenic mechanisms, improve diagnostic algorithms and evaluate novel therapeutic approaches within these complex disease entities.